Blog
New Clinical Research strengthens evidence for CAR T-cell treatment for blood cancer
23/12/2025
A new study by scientists at University College London and Great Ormond Street Hospital has demonstrated promising results in the treatment of T-cell acute Lymphoblastic Leukaemia (T-ALL), a rare and aggressive blood cancer What the study reveals. This groundbreaking research introduces BE-CAR7, a world-first base-edited Chimeric antigen receptor (CAR) T-cell therapy used in humans. The […]
What are Good Laboratory Practices (GLP) Guidelines, Purpose and Examples
22/12/2025
Good Laboratory Practice (GLP) is a set of criteria used to ensure quality assurance in non-clinical studies. GLP principles are concerned with the organisational processes by which studies are planned, performed, monitored, recorded, reported and archived. These guidelines support the integrity, reliability and traceability of safety data used for regulatory submissions. GLP is commonly applied […]
Alpha-1 Antitrypsin Deficiency: The Importance of Earlier Diagnosis and Clinical Research
09/12/2025
Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition that increases the risk of serious lung and liver disease. It occurs when the body produces too little of a protective protein called Alpha-1 Antitrypsin (AAT). Without adequate AAT, lung tissue becomes more susceptible to inflammation and progressive damage, while abnormal protein can build up in the […]
Duchenne Muscular Dystrophy: Causes, Symptoms, Inheritance and Clinical Research
14/11/2025
Duchenne muscular dystrophy (DMD) is a rare genetic disorder that causes progressive muscle weakness and wasting. It primarily affects males and is one of the most common and severe forms of muscular dystrophy. Understanding the causes, inheritance, and symptoms of Duchenne muscular dystrophy is essential for improving diagnosis, care, and advancing research into new therapies. […]
How does AI-enabled causal modelling support discussions with potential investors?
02/10/2025
Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered what AI-enabled causal modelling is, how it is different from other models, and where you might want to […]
Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?
02/10/2025
Can early utilisation of AI de-risk and accelerate clinical development for drug developers? Recent announcements suggest large pharma companies are betting big on AI. AstraZeneca recently announced a $247 million deal with an AI vendor to support identifying new oncology drug candidates[1]. Sanofi has announced a collaboration with two separate AI vendors, worth up to […]
The Impact of Clinical Trials on MS Research and Care
08/08/2025
Clinical trials are essential in advancing treatments for multiple sclerosis (MS). With no cure currently available, ongoing research is critical to uncovering new, more effective therapies. Simbec-Orion is a Clinical Research Organisation with nearly five decades of experience, specialising in oncology and rare diseases. This article explores the vital role that clinical trials play in […]
